References
- Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. Pharm Ther. 2015;40(4):277. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378521/
- O’Neill JIM. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Rev Antimicrob Resist. 2014;40(4) . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378521/
- Doron S, Davidson LE. Antimicrobial stewardship. Mayo Clin Proc. 2011;86(11):1113–1123. Elsevier. doi: 10.4065/mcp.2011.0358
- Ministerio de Salud Publica. Reporte de datos de resistencia a los antimicrobianos en Ecuador 2014-2018. 2018. 1–10. https://www.salud.gob.ec/wp-content/uploads/2019/08/gaceta_ram2018.pdf
- World Bank Group. Drug-resistant infections: a Threat to Our Economic Future. 2017. https://documents1.worldbank.org/curated/en/323311493396993758/pdf/final-report.pdf
- Organización Panamericana de la Salud. Resistencia a los antimicrobianos. 2023.
- Organización Mundial de la Salud. Resistencia a los antimicrobianos. 2023.
- da Silva JB Jr, Espinal M, Ramón-Pardo P. Resistencia a los antimicrobianos: tiempo para la acción. Rev Panam Salud Pública. 2020;44:44. doi: 10.26633/RPSP.2020.122
- Smith R, Coast J. The true cost of antimicrobial resistance. BMJ. 2013;346(mar11 3):f1493–f1493. doi: 10.1136/bmj.f1493
- García-Betancur JC, Appel TM, Esparza G, et al. Update on the epidemiology of carbapenemases in Latin America and the Caribbean. Expert Rev Anti Infect Ther. 2021;19(2):197–213. doi: 10.1080/14787210.2020.1813023
- Pearson MAJ, Galas M, Corso A, et al. Consenso latinoamericano para definir, categorizar y notificar patógenos multirresistentes, con resistencia extendida o panresistentes. Rev Panam Salud Pública. 2019;43. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6705331/
- Van Boeckel TP, Gandra S, Ashok A, et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis. 2014;14(8):742–750. doi: 10.1016/S1473-3099(14)70780-7
- Williams MR, Stedtfeld RD, Waseem H, et al. Implications of direct amplification for measuring antimicrobial resistance using point-of-care devices. Anal Methods. 2017;9(8):1229–1241. doi: 10.1039/C6AY03405E
- Lau HJ, Lim CH, Foo SC, et al. The role of artificial intelligence in the battle against antimicrobial-resistant bacteria. Curr Genet. 2021;67(3):421–429. doi: 10.1007/s00294-021-01156-5
- Hibstu Z, Belew H, Akelew Y, et al. Phage therapy: a different approach to fight bacterial infections. Biol Targets Ther. 2022;16:173–186. doi: 10.2147/BTT.S381237
- Cisek AA, Dąbrowska I, Gregorczyk KP, et al. Phage therapy in bacterial infections treatment: one hundred years after the discovery of bacteriophages. Curr Microbiol. 2017;74(2):277–283. doi: 10.1007/s00284-016-1166-x
- Nagel T, Musila L, Muthoni M, et al. Phage banks as potential tools to rapidly and cost-effectively manage antimicrobial resistance in the developing world. Curr Opin Virol Internet. 2022;53:101208. doi: 10.1016/j.coviro.2022.101208
- Qadir MI. Phage therapy: a modern tool to control bacterial infections. Pak J Pharm Sci. 2015;28. https://www.researchgate.net/profile/M-Qadir/publication/267877606_Phage_therapy_A_modern_tool_to_control_bacterial_infections/links/552b741a0cf2e089a3aa30d3/Phage-therapy-A-modern-tool-to-control-bacterial-infections.pdf
- de Freitas Almeida GM, Sundberg L-R. The forgotten tale of Brazilian phage therapy. Lancet Infect Dis. 2020;20(5):e90–e101. doi: 10.1016/S1473-3099(20)30060-8
- McCallin S, Sacher JC, Zheng J, et al. Current state of compassionate phage therapy. Viruses. 2019;11(4):343. doi: 10.3390/v11040343
- Pires DP, Costa AR, Pinto G, et al. Current challenges and future opportunities of phage therapy. FEMS Microbiol Rev. 2020;44(6):684–700. doi: 10.1093/femsre/fuaa017
- Khalid A, Lin RCY, Iredell JR. A phage therapy Guide for clinicians and basic scientists: background and highlighting applications for developing countries. Front Microbiol. 2021;11:11. doi: 10.3389/fmicb.2020.599906
- Bono LM, Mao S, Done RE, et al. Advancing phage therapy through the lens of virus host-breadth and emergence potential. Adv Virus Res. 2021;111:63–110.
- Gu Liu C, Green SI, Min L, et al. Phage-antibiotic synergy is driven by a unique combination of antibacterial mechanism of action and stoichiometry. MBio. 2020;11(4):e01462–20. doi: 10.1128/mBio.01462-20
- Melo LDR, Oliveira H, Pires DP, et al. Phage therapy efficacy: a review of the last 10 years of preclinical studies. Crit Rev Microbiol. 2020;46(1):78–99. doi: 10.1080/1040841X.2020.1729695
- Uyttebroek S, Chen B, Onsea J, et al. Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review. Lancet Infect Dis. 2022;22(8):e208–e220. doi: 10.1016/S1473-3099(21)00612-5
- Luong T, Salabarria A-C, Roach DR. Phage therapy in the resistance era: where do we stand and where are we going? Clin Ther. 2020;42(9):1659–1680. doi: 10.1016/j.clinthera.2020.07.014
- Diallo K, Dublanchet A. A century of clinical use of phages: a literature review. Antibiotics. 2023;12(4):751. doi: 10.3390/antibiotics12040751
- Torres‐Acosta MA, Clavijo V, Vaglio C, et al. Economic evaluation of the development of a phage therapy product for the control of salmonella in poultry. Biotechnol Prog. 2019;35(5):e2852. doi: 10.1002/btpr.2852